



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: November 6, 2009

To: Primary Clinical Research Associates

From: Linda S. Long
Protocol Development Coordinator

Re: N054C, Phase II Study of Sorafenib/Bevacizumab as Salvage Therapy in Patients with Metastatic Colorectal Cancer

The Eligibility Checklist and Blood Specimen Submission Form have been revised as follows:

Form Title	Brief Description of Edit
Eligibility Checklist	First Exclusion Criteria, page 3 of 5 read: <ul style="list-style-type: none">Was treatment held this cycle? . . . for at least 2 weeks after the last administration of sorafenib. Now reads: <ul style="list-style-type: none">Was treatment held this cycle? . . . for at least 6 months after the last administration of combined sorafenib and bevacizumab or for at least 2 weeks after the last administration of sorafenib.
Blood Specimen Submission Form	First bullet under Instructions read: <ul style="list-style-type: none">Complete . . . within 7 days of study entry (Baseline) or within 7 days of specimen collection. Corrected to read (per section 14.251): <ul style="list-style-type: none">Complete . . . ≤ 14 days of specimen collection.

If you have any questions, please feel free to contact me.

Enclosure